Currently, a phase II trial evaluating the efficacy of pan-RAF inhibitor naporafenib combined with ribociclib in patients with unresectable or metastatic NRAS-mutated melanoma is in progress (NCT04417621). The gene discussed is RAF1; the disease is melanoma.